15 October 2025
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
4 September 2025
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.
24 August 2025
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
22 August 2025
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
29 June 2025
Understand the significance of Ozempic and Mounjaro in the evolving landscape of diabetes care and weight management in South Africa.
29 June 2025
Explore the Aspen Pharmacare manufacturing dispute and its potential impact on core earnings for the 2025 financial year.
24 March 2025
The US FDA has warned Aspen Pharmacare, Africa's largest drugmaker, citing breaches in manufacturing standards for eye drops produced at its Gqeberha facility.
30 October 2024
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.